Immune System News -- ScienceDaily Recently, scientists found that some people who suffered from COVID-19 had auto-antibodies targeting their own type 1 interferons, which are important immune signaling proteins. Now, researchers conducted an in-depth study on 123 Japanese COVID-19 pati…
Scientists have discovered novel immune responses that help explain how some individuals avoid getting COVID-19. Using single-cell sequencing, researchers studied immune responses against SARS-CoV-2 infection in healthy adult volunteers. Not all expose…
A single large population of healer cells, called regulatory T cells, is whizzing around our body — not multiple specialist populations restricted to specific parts of the body as previously thought. These cells shut down inflammation and repair the c…
New study into the molecular pathways involved in sepsis is one step closer to rapid and targeted treatment of patients. New study into the molecular pathways involved in sepsis is one step closer to rapid and targeted treatment of patients.
A new study identifies NLRC5 as an innate immune sensor that plays a crucial role in PANoptotic cell death — making it a key therapeutic target.
Researchers have developed a new nanomedicine therapy that delivers anticancer drugs to lung cancer cells and enhances the immune system’s ability to fight cancer. The team showed promising results for the new therapy in cancer cells in the lab and in …
Researchers have found a new function for an existing protein. They discovered that TIMP-1, a protein traditionally known to prevent damage to the body’s cells and tissues, plays a critical role in the immune system’s defense against cancer. The findin…
A team of researchers has shown for the first time that fasting can reprogram the metabolism of natural killer cells, helping them to survive in the harsh environment in and around tumors, while also improving their cancer-fighting ability.
Researchers have not only identified how two immune cells work together to fight cancer but also revealed the cascade of molecules that help coordinate this attack.
In April, the FDA warned of risk of secondary cancers in people receiving CAR-T cell therapy. A large study now finds the risk is low and not related to the CAR-T cells.
